p.101 抽出テキスト

of 96 population-based studies with 331288 participants. Lancet Diabetes Endocrinol 2015;3:624–37. https://doi.org/10.1016/S2213-8587(15)00129-1 742. Wright AK, Suarez-Ortegon MF, Read SH, Kontopantelis E, Buchan I, Emsley R, et al. Risk factor control and cardiovascular event risk in people with type 2 diabetes in primary and secondary prevention settings. Circulation 2020;142:1925–36. https://doi. org/10.1161/circulationaha.120.046783 743. Adamsson Eryd S, Gudbjörnsdottir S, Manhem K, Rosengren A, Svensson A-M, Miftaraj M, et al. Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. BMJ 2016;354:i4070. https://doi.org/10.1136/bmj.i4070 744. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016;352:i717. https://doi.org/10.1136/bmj.i717 745. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015;313:603–15. https://doi.org/10.1001/jama.2014.18574 746. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 2017;35:922–44. https://doi.org/10. 1097/hjh.0000000000001276 747. Rahman F, McEvoy JW, Ohkuma T, Marre M, Hamet P, Harrap S, et al. Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus. Hypertension 2019;73:1291–9. https://doi.org/10.1161/hypertensionaha.118.12414 748. Agashe S, Petak S. Cardiac autonomic neuropathy in diabetes mellitus. Methodist Debakey Cardiovasc J 2018;14:251–6. https://doi.org/10.14797/mdcj-14-4-251 749. Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT. J Am Heart Assoc 2018;7:e009326. https://doi.org/10.1161/jaha.118.009326 750. Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW. Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care 2017;40:1733–8. https://doi.org/10.2337/dc17-1366 751. Brouwer TF, Vehmeijer JT, Kalkman DN, Berger WR, van den Born B-JH, Peters RJ, et al. Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials. Diabetes Care 2018;41: 1142–8. https://doi.org/10.2337/dc17-1722 752. Shi S, Gouskova N, Najafzadeh M, Wei LJ, Kim DH. Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial. BMJ Open 2021;11:e050335. https://doi.org/10.1136/ bmjopen-2021-050335 753. Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 2015;385:2047–56. https://doi.org/10. 1016/s0140-6736(14)62459-4 754. Ying A, Arima H, Czernichow S, Woodward M, Huxley R, Turnbull F, et al. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. Lancet 2015;385:867–74. https://doi.org/10.1016/ s0140-6736(14)61171-5 755. Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet 2021;398:1803–10. https://doi.org/10.1016/s0140-6736(21) 01920-6 756. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–23. https://doi. org/10.1016/s0140-6736(05)17741-1 757. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C, et al. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019;96:1048–50. https://doi.org/10.1016/j. kint.2019.07.012 758. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018;392:2052–90. https://doi.org/10.1016/s0140- 6736(18)31694-5 759. Ortiz A, Sanchez-Niño MD, Crespo-Barrio M, De-Sequera-Ortiz P, Fernández-Giráldez E, García-Maset R, et al. The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: keeping chronic kidney disease out of sight of health authorities will only magnify the problem. Nefrologia (Engl Ed) 2019;39:29–34. https://doi.org/ 10.1016/j.nefro.2018.09.002 760. Law JP, Pickup L, Pavlovic D, Townend JN, Ferro CJ. Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations. J Hum Hypertens 2023;37:1–19. https://doi.org/10. 1038/s41371-022-00751-4 761. Fay KS, Cohen DL. Resistant hypertension in people with CKD: a review. Am J Kidney Dis 2021;77:110–21. https://doi.org/10.1053/j.ajkd.2020.04.017 762. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet 2017; 389:1238–52. https://doi.org/10.1016/s0140-6736(16)32064-5 763. Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, Cass A, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013;347:f5680. https://doi. org/10.1136/bmj.f5680 764. Aggarwal R, Petrie B, Bala W, Chiu N. Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients. Hypertension 2019;73:1275–82. https:// doi.org/10.1161/hypertensionaha.119.12697 765. Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G, et al. Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med 2017;130:707–19.e8. https://doi.org/ 10.1016/j.amjmed.2017.01.004 766. Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 2013;185:949–57. https://doi.org/10.1503/cmaj. 121468 767. Tsai WC, Wu HY, Peng YS, Yang J-Y, Chen H-Y, Chiu Y-L, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med 2017;177:792–9. https://doi.org/10.1001/jamainternmed.2017.0197 768. Thompson S, Wiebe N, Padwal RS, Gyenes G, Headley SAE, Radhakrishnan J, et al. The effect of exercise on blood pressure in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2019;14:e0211032. https://doi. org/10.1371/journal.pone.0211032 769. Huang M, Lv A, Wang J, Xu N, Ma G, Zhai Z, et al. Exercise training and outcomes in hemodialysis patients: systematic review and meta-analysis. Am J Nephrol 2019;50: 240–54. https://doi.org/10.1159/000502447 770. Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3–5: a network meta-analysis of randomised clinical trials. Drugs 2020;80: 797–811. https://doi.org/10.1007/s40265-020-01290-3 771. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244–52. https://doi.org/10.7326/0003-4819-139-4-200308190-00006 772. Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 2016;67:728–41. https://doi.org/10.1053/j.ajkd.2015.10.011 773. Wu HY, Huang JW, Lin HJ, Liao W-C, Peng Y-S, Hung K-Y, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ 2013;347:f6008. https://doi.org/10.1136/bmj.f6008 774. Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 2021;385:2507–19. https://doi.org/10.1056/NEJMoa2110730 775. Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, et al. Implications of early decline in eGFR due to intensive BP control for cardiovascular outcomes in SPRINT. J Am Soc Nephrol 2019;30:1523–33. https://doi.org/10.1681/asn.2018121261 776. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388: 117–27. https://doi.org/10.1056/NEJMoa2204233 777. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383: 1436–46. https://doi.org/10.1056/NEJMoa2024816 778. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 385:2252–63. https://doi.org/10.1056/NEJMoa2110956 779. Ku E, McCulloch CE, Inker LA, Tighiouart H, Schaefer F, Wühl E, et al. Intensive BP control in patients with CKD and risk for adverse outcomes. J Am Soc Nephrol 2023;34:385–93. https://doi.org/10.1681/asn.0000000000000072 780. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60. https://doi.org/10.1056/ NEJMoa011303 781. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9. https://doi.org/10.1056/ NEJMoa011161 782. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857–63. https://doi.org/10.1016/S0140-6736(96)11445-8 Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026